Teva Pharmaceutical Industries Ltd banner

Teva Pharmaceutical Industries Ltd
TASE:TEVA

Watchlist Manager
Teva Pharmaceutical Industries Ltd Logo
Teva Pharmaceutical Industries Ltd
TASE:TEVA
Watchlist
Price: 9 902 ILS 0.43%
Market Cap: ₪111.5B

Teva Pharmaceutical Industries Ltd
Research & Development

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Teva Pharmaceutical Industries Ltd
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
Teva Pharmaceutical Industries Ltd
TASE:TEVA
Research & Development
-$1B
CAGR 3-Years
-7%
CAGR 5-Years
0%
CAGR 10-Years
4%
Sol Gel Technologies Ltd
NASDAQ:SLGL
Research & Development
-$24.4m
CAGR 3-Years
-22%
CAGR 5-Years
4%
CAGR 10-Years
N/A
PolyPid Ltd
NASDAQ:PYPD
Research & Development
-$23.8m
CAGR 3-Years
5%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
Mediwound Ltd
NASDAQ:MDWD
Research & Development
-$12.8m
CAGR 3-Years
-9%
CAGR 5-Years
N/A
CAGR 10-Years
-9%
T
Tikun Olam Cannbit Pharmaceuticals Ltd
TASE:TKUN
Research & Development
-₪145k
CAGR 3-Years
71%
CAGR 5-Years
35%
CAGR 10-Years
N/A
R
Rekah Pharmaceutical Industry Ltd
TASE:REKA
Research & Development
-₪4.4m
CAGR 3-Years
-13%
CAGR 5-Years
-22%
CAGR 10-Years
-5%
No Stocks Found

Teva Pharmaceutical Industries Ltd
Glance View

Teva Pharmaceutical Industries Ltd., a titan in the global pharmaceutical landscape, has navigated the intricate world of pharmaceuticals with a blend of strategic vision and operational efficiency. Founded in 1901 and headquartered in Israel, Teva has become synonymous with the production of affordable generic medications, a key pillar of its business model. The company's narrative is one of adaptability and foresight, having positioned itself as a leader in the generic drug sector by leveraging economies of scale and a vast distribution network. By acquiring and integrating smaller pharmaceutical firms over the years, Teva has expanded its portfolio to include a vast array of treatments that address a broad spectrum of therapeutic areas. This strategic expansion has enabled the company to offer nearly the same efficacy as brand-name drugs at a fraction of the cost, thus capturing significant market share and delivering value to both patients and healthcare systems worldwide. Beyond its prowess in generics, Teva has carved a niche in the specialty medicines market, focusing on innovative therapies that address complex conditions such as multiple sclerosis, migraine, and movement disorders. This dual-track approach to growth allows Teva to balance the volume-driven nature of the generics market with the higher margins offered by specialty drugs. The synthesis of these two facets – comprehensive generic offerings and targeted specialty pharmaceuticals – underpins Teva's revenue streams. Through a combination of robust pipeline development, strategic partnerships, and a commitment to operational excellence, Teva navigates the challenges of a competitive industry marked by ever-evolving regulations and pricing pressures, striving to maintain its status as a reliable provider of healthcare solutions on a global scale.

TEVA Intrinsic Value
HIDDEN
Show

See Also

What is Teva Pharmaceutical Industries Ltd's Research & Development?
Research & Development
-1B USD

Based on the financial report for Dec 31, 2025, Teva Pharmaceutical Industries Ltd's Research & Development amounts to -1B USD.

What is Teva Pharmaceutical Industries Ltd's Research & Development growth rate?
Research & Development CAGR 10Y
4%

Over the last year, the Research & Development growth was -2%. The average annual Research & Development growth rates for Teva Pharmaceutical Industries Ltd have been -7% over the past three years , and 4% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett